NCT05002933View on ClinicalTrials.gov

A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period

PHASE4CompletedINTERVENTIONAL
Enrollment

570

Participants

Timeline

Start Date

May 20, 2021

Primary Completion Date

February 24, 2023

Study Completion Date

February 24, 2023

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Insulin glargine 300 U/ml

Solution for injection Subcutaneous injection

Trial Locations (1)

Unknown

Investigational Sites, China

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT05002933 - A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period | Biotech Hunter | Biotech Hunter